Review
Open access
Sep 2026
STING-mediated tumor microenvironment remodeling: turning adaptive resistance into therapeutic vulnerability
It is proposed that rational combinations of STING agonists with Fc-engineered PD-L1/PD-L2-targeting antibodies, guided by dynamic and spatial biomarkers, could overcome resistance to conventional immune checkpoint blockade in tumors with minimal T-cell infiltration but targetable tumor vasculature.
Akash R. Boda, E. Bolli, A. Salameh et al.
· Frontiers in Immunology · 0 citations